An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy.
Alberto JuanFrancisco J CimasIván BravoAtanasio PandiellaAlberto OcañaCarlos Alonso-MorenoPublished in: Pharmaceutics (2020)
Nanoparticles (NPs) are promising drug delivery systems (DDS) for identifying and treating cancer. Active targeting NPs can be generated by conjugation with ligands that bind overexpressed or mutant cell surface receptors on target cells that are poorly or not even expressed on normal cells. Receptor-mediated endocytosis of the NPs occurs and the drug is released inside the cell or in the surrounding tissue due to the bystander effect. Antibodies are the most frequently used ligands to actively target tumor cells. In this context, antibody-based therapies have been extensively used in HER2+ breast cancer. However, some patients inherently display resistance and in advanced stages, almost all eventually progress. Functionalized NPs through conjugation with antibodies appear to be a promising strategy to optimize targeted therapies due to properties related to biocompatibility, suitable delivery control and efficiency of functionalization. This review is focused on the different strategies to conjugate antibodies into polymeric NPs. Recent antibody conjugation approaches applied to the improvement of breast cancer therapy are highlighted in this review.
Keyphrases
- cancer therapy
- drug delivery
- induced apoptosis
- cell cycle arrest
- cell surface
- oxide nanoparticles
- end stage renal disease
- ejection fraction
- newly diagnosed
- multidrug resistant
- chronic kidney disease
- squamous cell carcinoma
- oxidative stress
- cell therapy
- stem cells
- papillary thyroid
- emergency department
- cell death
- endoplasmic reticulum stress
- drug release
- mesenchymal stem cells
- signaling pathway
- mass spectrometry
- young adults
- walled carbon nanotubes
- electronic health record
- high resolution
- squamous cell
- cell proliferation
- wild type